FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3136286795> ?p ?o ?g. }

• W3136286795 endingPage "1234" @default.
• W3136286795 startingPage "1225" @default.
• W3136286795 abstract "We prospectively assessed, with predefined criteria, the location and rates of all femur fractures (hip, subtrochanteric/femoral shaft [ST/FS], including atypical [AFF] and distal fractures) in women at increased fracture risk during treatment with the cathepsin K inhibitor, odanacatib (ODN), or placebo over 5 years in the Long-Term ODN Fracture Trial (LOFT and LOFT Extension [NCT00529373, EudraCT 2007-002693-66]). ODN was an investigational antiresorptive agent previously in development as an osteoporosis treatment that, unlike bisphosphonates, reduces bone formation only transiently. Women aged ≥65 years with a bone mineral density (BMD) T-score ≤-2.5 at the total hip (TH) or femoral neck (FN) or with a radiographic vertebral fracture and T-scores ≤-1.5 at the TH or FN were randomized (1:1) to receive ODN 50 mg/week or placebo. All patients received vitamin D3 (5600 IU/week) and calcium (total 1200 mg/d); the analysis included 16,071 women. Rates of all adjudicated low-energy femoral fractures were 0.38 versus 0.58/100 patient-years for ODN and placebo, respectively (hazard ratio [HR] = 0.65; 95% confidence interval [CI] 0.51-0.82; nominal p < .001), and for low-energy hip fractures were 0.29 versus 0.56/100 patient-years, respectively (HR = 0.52; 95% CI 0.40-0.67; p < .001). The cumulative incidence of combined hip and ST/FS or hip fractures alone in the ODN group was consistently lower than in the placebo group (1.93% versus 3.11% for combined fractures and 1.53% versus 3.03% for hip fractures at 5 years, respectively). However, low-energy ST/FS fractures were more frequent in ODN-treated women than in placebo-treated women (24 versus 6, respectively). Among these, 12 fractures were adjudicated as AFF in 10 patients treated with ODN (0.03/100 patient-years) compared with none in the 6 placebo-treated women (estimated difference 0.03; 95% CI 0.02-0.06). These results provide insight into possible pathogeneses of AFF, suggesting that the current criteria for diagnosing these fractures may need to be reconsidered. © 2021 American Society for Bone and Mineral Research (ASBMR).." @default.
• W3136286795 created "2021-03-29" @default.
• W3136286795 creator A5010429279 @default.
• W3136286795 creator A5028056767 @default.
• W3136286795 creator A5032638450 @default.
• W3136286795 creator A5033051531 @default.
• W3136286795 creator A5039354344 @default.
• W3136286795 creator A5046421559 @default.
• W3136286795 creator A5048725197 @default.
• W3136286795 creator A5057643841 @default.
• W3136286795 creator A5077748517 @default.
• W3136286795 creator A5088520557 @default.
• W3136286795 creator A5088692766 @default.
• W3136286795 creator A5088773176 @default.
• W3136286795 date "2021-04-27" @default.
• W3136286795 modified "2023-10-03" @default.
• W3136286795 title "Incidence of Hip and Subtrochanteric/Femoral Shaft Fractures in Postmenopausal Women With Osteoporosis in the Phase 3 Long‐Term Odanacatib Fracture Trial" @default.
• W3136286795 cites W1237486756 @default.
• W3136286795 cites W1964983463 @default.
• W3136286795 cites W1999616004 @default.
• W3136286795 cites W2000411736 @default.
• W3136286795 cites W2009873137 @default.
• W3136286795 cites W2028917977 @default.
• W3136286795 cites W2036074421 @default.
• W3136286795 cites W2039758450 @default.
• W3136286795 cites W2043539287 @default.
• W3136286795 cites W2055677813 @default.
• W3136286795 cites W2064799367 @default.
• W3136286795 cites W2151825217 @default.
• W3136286795 cites W2169251377 @default.
• W3136286795 cites W2287074011 @default.
• W3136286795 cites W2338130968 @default.
• W3136286795 cites W2520995084 @default.
• W3136286795 cites W2524977260 @default.
• W3136286795 cites W2603141520 @default.
• W3136286795 cites W2619448414 @default.
• W3136286795 cites W2624963411 @default.
• W3136286795 cites W2736408541 @default.
• W3136286795 cites W2754720807 @default.
• W3136286795 cites W2889208018 @default.
• W3136286795 cites W2982398656 @default.
• W3136286795 cites W3009766857 @default.
• W3136286795 cites W561627921 @default.
• W3136286795 doi "https://doi.org/10.1002/jbmr.4284" @default.
• W3136286795 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33724542" @default.
• W3136286795 hasPublicationYear "2021" @default.
• W3136286795 type Work @default.
• W3136286795 sameAs 3136286795 @default.
• W3136286795 citedByCount "9" @default.
• W3136286795 countsByYear W31362867952022 @default.
• W3136286795 countsByYear W31362867952023 @default.
• W3136286795 crossrefType "journal-article" @default.
• W3136286795 hasAuthorship W3136286795A5010429279 @default.
• W3136286795 hasAuthorship W3136286795A5028056767 @default.
• W3136286795 hasAuthorship W3136286795A5032638450 @default.
• W3136286795 hasAuthorship W3136286795A5033051531 @default.
• W3136286795 hasAuthorship W3136286795A5039354344 @default.
• W3136286795 hasAuthorship W3136286795A5046421559 @default.
• W3136286795 hasAuthorship W3136286795A5048725197 @default.
• W3136286795 hasAuthorship W3136286795A5057643841 @default.
• W3136286795 hasAuthorship W3136286795A5077748517 @default.
• W3136286795 hasAuthorship W3136286795A5088520557 @default.
• W3136286795 hasAuthorship W3136286795A5088692766 @default.
• W3136286795 hasAuthorship W3136286795A5088773176 @default.
• W3136286795 hasBestOaLocation W31362867951 @default.
• W3136286795 hasConcept C120665830 @default.
• W3136286795 hasConcept C121332964 @default.
• W3136286795 hasConcept C126322002 @default.
• W3136286795 hasConcept C126894567 @default.
• W3136286795 hasConcept C141071460 @default.
• W3136286795 hasConcept C142724271 @default.
• W3136286795 hasConcept C204787440 @default.
• W3136286795 hasConcept C207103383 @default.
• W3136286795 hasConcept C27081682 @default.
• W3136286795 hasConcept C2775854910 @default.
• W3136286795 hasConcept C2776541429 @default.
• W3136286795 hasConcept C2776886416 @default.
• W3136286795 hasConcept C2778885795 @default.
• W3136286795 hasConcept C2780554211 @default.
• W3136286795 hasConcept C44249647 @default.
• W3136286795 hasConcept C61511704 @default.
• W3136286795 hasConcept C71924100 @default.
• W3136286795 hasConceptScore W3136286795C120665830 @default.
• W3136286795 hasConceptScore W3136286795C121332964 @default.
• W3136286795 hasConceptScore W3136286795C126322002 @default.
• W3136286795 hasConceptScore W3136286795C126894567 @default.
• W3136286795 hasConceptScore W3136286795C141071460 @default.
• W3136286795 hasConceptScore W3136286795C142724271 @default.
• W3136286795 hasConceptScore W3136286795C204787440 @default.
• W3136286795 hasConceptScore W3136286795C207103383 @default.
• W3136286795 hasConceptScore W3136286795C27081682 @default.
• W3136286795 hasConceptScore W3136286795C2775854910 @default.
• W3136286795 hasConceptScore W3136286795C2776541429 @default.
• W3136286795 hasConceptScore W3136286795C2776886416 @default.
• W3136286795 hasConceptScore W3136286795C2778885795 @default.
• W3136286795 hasConceptScore W3136286795C2780554211 @default.
• W3136286795 hasConceptScore W3136286795C44249647 @default.
• W3136286795 hasConceptScore W3136286795C61511704 @default.

• next